Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSING: Tezepelumab in Eosinophilic Esophagitis
jRCT2021230017Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of tezepelumab in eosinophilic esophagitis (EoE) (3 arms), sponsored by AstraZeneca. Primary endpoints: Histologic response at Week 24 and Change in Dysphagia Symptom Questionnaire (DSQ) score. Started Oct 2023; status: active, not recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on jRCT2021230017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230017.